



1 **Address for correspondence:**

2 Professor Jill Pell

3 Director of the Institute of Health and Wellbeing

4 University of Glasgow

5 1 Lilybank Gardens

6 Glasgow G12 8RZ

7 United Kingdom

8 [Jill.pell@glasgow.ac.uk](mailto:Jill.pell@glasgow.ac.uk)

9

10

11 Abstract word count 274

12 Main text word count 3,317

13 Tables 5

14 Supplementary Tables 2

15 Supplementary Figures 1

16 Number of references 34

17

18

19

20

1 **Abstract**

2 Background

3 Shielding (extended self-isolation) of people judged, a priori, to be at high-risk from COVID-  
4 19 has been used by some countries to protect the individuals and reduce demand on health  
5 services. It is unclear how well this strategy works in either regard.

6 Methods

7 A general population study was conducted using linked primary care, prescribing, laboratory,  
8 hospital and death records up to end of May 2020. Poisson regression models and population  
9 attributable fractions were used to compare COVID-19 outcomes by overall risk category,  
10 and individual risk criteria: confirmed infection, hospitalisation, intensive care unit (ICU)  
11 admission, population mortality and case-fatality.

12 Results

13 Of the 1.3 million population, 32,533 (2.47%) had been advised to shield, a further 347,374  
14 (26.41%) were classified as moderate risk. Testing for COVID-19 was more common in the  
15 shielded (6.75%) and moderate (1.99%) than low (0.72%) risk categories. Referent to low-  
16 risk, the shielded group had higher risk of confirmed infection (RR 7.91, 95% 7.01-8.92),  
17 case-fatality (RR 5.19, 95% CI 4.12-6.53) and population mortality (RR 48.64, 95% 37.23-  
18 63.56). The moderate risk had intermediate risk of confirmed infection (RR 4.11, 95% CI  
19 3.82-4.42) and population mortality (RR 26.10, 95% CI 20.89-32.60), but had comparable  
20 case-fatality (RR 5.13, 95% CI 4.24-6.21) to the shielded, and accounted for a higher  
21 proportion of deaths (PAF 75.27% vs 13.38%). Age  $\geq 70$  years made the largest contribution  
22 to deaths (49.53%) and was associated with an 8-fold risk of infection, 7-fold case-fatality  
23 and 74-fold mortality.

24 Conclusions

1 Shielding has not been effective at preventing deaths in those with highest risk. To be  
2 effective as a population strategy, shielding criteria would need to be widely expanded to  
3 include other criteria, such as the elderly.

4

5 **Keywords (MeSH terms):**

6 Cohort studies; COVID-19; epidemiology; vulnerable populations

7

8

## 1 **Background**

2

3 Early in the COVID-19 pandemic, one of the greatest concerns was that the demand on  
4 health services would exceed capacity in terms of hospitalisations, admissions to intensive  
5 care units (ICU) and requirement for ventilation <sup>1</sup>. Based on past experience, it was assumed  
6 that sub-groups of the population would have worse prognosis and, therefore, contribute  
7 disproportionately to adverse outcomes and healthcare demands.

8

9 Asian countries have generally relied solely on population-wide strategies <sup>2</sup>. Early,  
10 widespread ‘test, trace, isolate’ strategies were made possible by higher testing capacity and a  
11 greater willingness to monitor and enforce compliance. In contrast, European countries have  
12 generally adopted a two-pronged approach <sup>2</sup>, whereby general population interventions, such  
13 as physical distancing and hand hygiene, designed to reduce transmission in the population as  
14 a whole, have been supplemented by shielding of those assumed to be at higher risk. Notably,  
15 Sweden, an outlier in having not applied lock-down, nonetheless mandated shielding<sup>3</sup>.  
16 Studies suggest that shielding can have negative physical and psychological impact on those  
17 required to undertake strict isolation over a protracted period.<sup>4,5</sup>

18

19 In the United Kingdom, a Shielded Patient List (initially referred to as the Vulnerable Patient  
20 List) was produced comprising two categories(Supplementary Table 1)<sup>6</sup>. The two groups  
21 have been labelled high risk, highest risk or clinically extremely vulnerable and moderate  
22 risk, at risk or clinically vulnerable by various UK organisations. For the purposes of this  
23 study they are referred to as shielded and moderate risk, with the remaining population  
24 labelled low risk. In the United Kingdom, the shielded group received individual letters  
25 strongly recommending that they self-isolate over a protracted period, by not leaving their

1 homes and avoiding non-essential contact with their household members, and were provided  
2 with support at home such as the delivery of food packages. The advice to the moderate risk  
3 category was simply to be vigilant in adhering to the general population measures.

4

5 The definitions of high and moderate risk were based largely on expert opinion informed by  
6 our understanding of previous viruses and the critical need for better definition of high risk  
7 has been highlighted <sup>7</sup>. Studies are emerging of the individual risk factors associated with  
8 COVID-19 outcomes. For example, among two million UK community-based app users self-  
9 reported heart disease, kidney disease, lung disease, diabetes and obesity were associated  
10 with self-reported hospital admission and respiratory support for COVID-19 <sup>8</sup>. Similarly,  
11 linkage of primary care records of 17 million people in England demonstrated that a wide  
12 range of long-term conditions were associated with in-hospital death from COVID-19  
13 including: respiratory, heart, liver and kidney disease, diabetes, cancers, stroke and organ  
14 transplantation <sup>9</sup>. Unfortunately, the investigators did not have access to deaths in the  
15 community. COVID-19 risk scores are being developed in an attempt to improve  
16 identification of high risk individuals who would be advised to shield <sup>10</sup> but attempts to  
17 investigate the potential contribution of a shielding strategy to population-level outcomes and  
18 healthcare demands have so far been limited to abstract mathematical modelling<sup>11-19</sup>.

19

20 The aims of this study were to compare those classified, a priori, as high risk (and therefore  
21 advised to shield) and those classified as moderate and low risk, in terms of their individual  
22 risk of COVID-19 infection and outcomes and the extent to which they accounted for  
23 COVID-19 related outcomes at a population level.

24

25 **Methods**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

We conducted a general population cohort study of all 1.3 million residents of NHS Greater Glasgow and Clyde (NHS GGC) in Scotland. The Community Health Index (CHI), a unique identifier attached to all health records in Scotland, was used to undertake individual-level record linkage via exact matching of nine databases: Community Health Index (CHI) register, NHS GGC Shielding List, Egton Medical Information Systems (EMIS) and Vision, Electronic Communication of Surveillance in Scotland (ECOSS), Prescribing Information System (PIS), Rapid Preliminary Inpatient Data (RAPID), and death certificates.

The CHI register provided sociodemographic information (age, sex, socioeconomic deprivation). Socioeconomic deprivation was derived from the Scottish Index of Multiple Deprivation (SIMD), an area-based measure derived from seven domains - income, education, health, employment, crime, housing, and access to services – which was categorised into general population quintiles. The Electronic Communication of Surveillance in Scotland (ECOSS) database collects laboratory data on infectious diseases, including test date and result. EMIS and Vision are the primary care electronic health record systems used in NHS GGC. Data are extracted using Albasoft software. The PIS collects data on all medications prescribed by community-based healthcare workers, including general practitioners. The RAPID database collects real-time data on every patient admitted to a general (i.e. non-psychiatric) hospital in Scotland including dates of admission and discharge, and type of ward (e.g. ICU) but does not record disease codes. Subsequently, the Scottish Morbidity Record 01 (SMR01) records the same information, in addition to disease codes. Death certificates provide the date and cause of death for all deaths, whether they occur in-

1 hospital or in the community. Follow-up data were available until the end of May 2020,  
2 before the recommendation to shield was lifted.  
3  
4 Supplementary Table 1 lists the criteria for the shielded and medium risk categories being  
5 applied in the United Kingdom at the time of data extraction. All remaining patients are  
6 categorised as low risk. The Scottish list of high-risk individuals is compiled, and regularly  
7 updated, centrally using data obtained from a number of sources including Albasoft  
8 extraction of general practice data, SMR01 (hospital admissions), SMR06 (cancer registry),  
9 national disease registries, and the PIS. The list is sent to individual general practitioners to  
10 check for completeness and accuracy, before letters are sent to patients with advice to shield.  
11 The NHS GGC Shielding List contains the validated data including the criterion satisfied. We  
12 ascertained people who met the criteria for moderate risk via Albasoft extraction of EMIS  
13 and Vision data and PIS data.  
14  
15 Separate models were conducted for two exposure variables: overall risk category (low,  
16 moderate or high) and the individual criteria for the moderate and high-risk categories. The  
17 four general population outcomes investigated were: confirmed COVID-19 infection;  
18 COVID-19 related hospitalisation; COVID-19 related ICU admission; COVID-19 related  
19 mortality. The three outcomes investigated among those with confirmed infection were;  
20 COVID-19 related hospitalisation; COVID-19 related ICU admission; and COVID-19 related  
21 case fatality.  
22  
23 Laboratory-confirmed cases were defined as patients who had a positive PCR test for  
24 COVID-19. Clinically-confirmed cases were defined as patients who either had a positive  
25 PCR test or who died from COVID-19 without testing. COVID-related deaths were defined



1 as deaths with International Classification of Diseases 10<sup>th</sup> revision (ICD-10) code U07.1 or  
2 U07.2 recorded on the death certificate. COVID-related hospitalisation was defined as an  
3 SMR01 record of hospitalisation with an ICD code U07.1 or U07.2 or, for more recent  
4 admissions, a RAPID record of hospitalisation with a positive COVID-19 test taken between  
5 two weeks before and two days after admission to hospital. ICU admission during such  
6 hospitalisations was assumed to be COVID-related.

7

8 The sociodemographic characteristics of people were compared by risk category using chi-  
9 square tests. Poisson regression models with robust standard errors were used to compare the  
10 risk ratios (RR) for the high and moderate risk categories referent to the low risk category for  
11 each outcome in turn. The models were run univariately and then adjusted for sex and SIMD  
12 quintiles as potential confounders. Age was not included as a covariate because it was a  
13 moderate risk criterion. The models were re-run using the individual criteria for the high and  
14 moderate risk categories as the exposure variables, referent to the low risk category.

15

16 Population attributable fractions (PAFs) were calculated, from prevalence and adjusted RR,  
17 to determine the proportion of each outcome that could be attributed to being high and  
18 moderate risk, as well as the proportion due to each of the individual criteria. The PAFs of  
19 individual criteria were proportionally calibrated so that the sum of PAFs of individual  
20 criteria equated to the overall PAF of the relevant risk category. PAF confidence intervals  
21 were estimated using bootstrapping (x 1000).

22

23 Ethical approvals

24

1 The study was approved by the NHS Greater Glasgow and Clyde Primary Care Information  
2 Sharing Group and the NHS Greater Glasgow and Clyde Local Privacy Advisory Committee  
3 (LPAC) (Reference GSH/20RM005) and was covered by the generic Safe Haven Research  
4 Ethics Committee approval (GSH20RM005\_COVID\_Community).

5

## 6 **Results**

7

8 Of the 1,315,071 people registered with general practitioners in NHS Greater Glasgow and  
9 Clyde, 32,533 (2.47%) were recorded as requiring shielding and 347,374 (26.41%) were  
10 classified, a priori, as being at moderate risk. Of the 32,533 people in the shielded group,  
11 18,147 (55.78%) had severe respiratory disease, 6,761 (20.78%) were on renal dialysis, 5,349  
12 (16.44%) were on immunosuppressive therapies, 2,491 (7.66%) had specific cancers, 1,245  
13 (3.83%) had received organ transplants, and less than five were pregnant and had severe heart  
14 disease. Of the 347,374 people classified as moderate risk, 160,215 (46.12%) had  
15 hypertension, 151,865 (43.72%) had chronic lung disease, 139,568 (40.18%) were at least 70  
16 years of age, 64,358 (18.53%) had diabetes, 48,571 (13.98%) had heart disease, and 1,195  
17 (0.34%) had a weakened immune system.

18

### 19 Shielded and moderate risk categories

20

21 Overall, 15,865 (1.21%) people had been tested for COVID-19. The likelihood of having  
22 been tested increased with age, was higher in women and was higher in the moderate-risk  
23 category and highest in the shielded group (Table 1). Overall, 3,348 (0.25%) people had  
24 confirmed COVID-19 infection. The likelihood of laboratory-confirmed COVID-19 infection  
25 followed similar patterns as testing. It increased with age, was higher in women, and was

1 highest in the shielded group and lowest in the low-risk category (Table 2). After adjustment  
2 for sex and deprivation quintile, the risk of laboratory-confirmed infection remained higher in  
3 the moderate-risk category and highest in the shielded group (Table 3).

4

5 Overall, 1,661 people were admitted to hospital for COVID-19. Within the general  
6 population, hospitalisations increased with age but were comparable between men and  
7 women (Table 2). Hospitalisations were more common in the moderate-risk category and  
8 most common in the shielded group (Table 2) and remained so after adjustment for sex and  
9 deprivation quintile (Table 3). Overall, 122 people were admitted to ICU wards for COVID-  
10 19. ICU admissions were significantly more common among people aged 45-64 years of age  
11 than among older people (Table 2). Compared with the low risk category, the shielded group  
12 were 18 times more likely to be hospitalised but only 4 times more likely to be admitted to  
13 ICU (Table 3). Overall, 1,027 (0.08%) people died from COVID-19. Within the general  
14 population, mortality increased with age but was similar in men and women (Table 2).  
15 Population mortality was higher in the moderate-risk category and highest in the shielded  
16 group (Table 2) and remained so after adjustment for sex and deprivation quintile (Table 3).

17

18 Among the sub-group with laboratory-confirmed (test-positive) COVID-19 infection, 1,661  
19 (49.6%) were hospitalised. Hospitalisations increased with age but were comparable between  
20 men and women (Table 4). The moderate-risk category was more likely to be hospitalised  
21 and the shielded group most likely (Table 4) and remained so after adjustment for age and  
22 deprivation quintile (Table 5). Among the sub-group with laboratory-confirmed COVID-19  
23 infection, ICU admissions were more common in men and more common in people aged 45-  
24 64 years than those older (Table 4). Low risk cases were more likely to be admitted to ICU  
25 than those in the moderate-risk category and shielded groups (Tables 4 & 5). Among the sub-

1 group with clinically-confirmed (test-positive or COVID-19 related death) COVID-19  
2 infection, 1,027 (26.70%) died (Table 4). Case-fatality increased by age and was higher in  
3 men than women. It was lowest in the low-risk category but not significantly different in the  
4 moderate-risk category and shielded group ( $p=0.64$ ) (Table 5).

5  
6 The shielded group accounted for 8.58% of laboratory-confirmed COVID-19 infections,  
7 15.45% of COVID-19 hospitalisations, 4.91% of ICU admissions and 13.38% of COVID-19  
8 related deaths (Supplementary Table 2). The corresponding figures for the moderate risk  
9 category were 41.22%, 61.33%, 20.78% and 75.27%. To prevent at least 80% of deaths,  
10 28.8% of the population would have had to receive the current level of shielding including  
11 those with five criteria currently classified as moderate risk (Supplementary Figure 1).

12

### 13 Individual risk criteria

14

15 Due to insufficient numbers, the models for individual risk criteria could not be run for  
16 pregnant women with severe heart disease or for COVID-19 related ICU admission in the  
17 high-risk category. All of the remaining individual risk criteria were associated with higher  
18 likelihood of being tested for COVID-19 (Table 1) and higher likelihood of having  
19 laboratory-confirmed infection (Table 2). They were all associated with higher risk of  
20 hospitalisation, population mortality (Table 3) and case-fatality (Table 5) independent of sex  
21 and deprivation quintile. Among the moderate-risk category criteria, age  $\geq 70$  years and  
22 weakened immune system had risks of population mortality (Table 3) and case-fatality (Table  
23 5) that were at least as high as the overall shielded group. Apart from the 0.13% of people  
24 with relevant rare diseases and inborn errors of metabolism, the strongest associations were  
25 observed for those aged  $\geq 70$  years who were eight times more likely to have confirmed

1 infection (Table 3); seven times more likely to die following confirmation of infection (Table  
2 5); and seventy four times as likely to die overall (Table 3) compared with those in low risk  
3 category. Being more than 70 years of age accounted for 17.45% of confirmed COVID-19  
4 infections, 22.90% of COVID-19 related hospitalisations, and 49.53% of COVID-19 related  
5 deaths (Supplementary Table 2). Among those admitted to hospital for COVID-19, the  
6 likelihood of being admitted to ICU was significantly lower for all of the individual risk  
7 criteria included in the moderate risk category, other than diabetes (Table 5). In particular,  
8 hospitalised patients over 70 years of age were 14 times less likely to be admitted to ICU than  
9 low risk hospitalised patients (Table 5).

10

## 11 **Discussion**

12

13 The 2.47% of people who had been advised to shield were, nonetheless, eight times more  
14 likely to have confirmed infections than the low risk category, five times more likely to die  
15 following confirmed infection and 49 times more likely to die from covid-19 overall. Whilst  
16 selective testing of potential cases might explain the first outcome, it does not explain higher  
17 overall mortality which suggests that the shielding strategy has not been as effective as was  
18 hoped.

19

20 One quarter of the population were classified as moderate risk and not advised to shield.  
21 Nonetheless, they were four times more likely to have confirmed infections than the low risk  
22 category, five times more likely to die following confirmed infection and 26 times more  
23 likely to die overall, suggesting that consideration should be given to expanding the shielding  
24 criteria to include many currently classified as moderate risk. In particular, older age needs to

1 be considered since the elderly are both at high individual risk and contribute significantly to  
2 population burden due to their relatively high numbers.

3

4 Paradoxically, people in the shielded and moderate risk categories were less likely to be  
5 admitted to ICU following hospitalised for COVID-19 in spite of their poor prognosis.

6 Patients over 70 years were particularly unlikely to be admitted to ICU. This is likely to be  
7 due to selective admission policies applied in order to avoid demand exceeding supply, as  
8 experienced by some other countries. This finding reinforces the importance of prevention in  
9 those with the worst prognosis.

10

#### 11 Comparison with existing literature

12

13 Our finding of 26.41% percent of people satisfying the moderate risk criteria is consistent  
14 with the limited existing evidence. A previous study linking English primary and secondary  
15 care records on 3.9 million people reported that 20% of the population satisfied similar  
16 criteria<sup>20</sup>. Similarly, a study using data from the Global Burden of Diseases Study estimated  
17 that 22% of the global population are at increased risk of severe COVID-19 disease<sup>21</sup>. A USA  
18 study using data from the Behavioral Risk Factor Surveillance System reported that 45.4% of  
19 444,649 adults had one or more of a longer list of morbidities that may be associated with  
20 higher risk from COVID-19<sup>22</sup>. Another USA study estimated that 14.2% of participants in the  
21 National Health Interview Survey had more than two-fold risk and 1.6% had more than 10-  
22 fold risk<sup>23</sup>.

23

24 The evidence on COVID-19 related complications among those people classified as high risk,  
25 and therefore advised to shield, has mainly come from case series, expert opinions,

1 unpublished reports. Evidence from case reports found higher COVID-19 related  
2 complications among organ transplant recipients<sup>24,25</sup>, patients receiving active cancer  
3 treatment (chemotherapy, radiotherapy or immunotherapy)<sup>26,27</sup>, and patients with  
4 haematological cancers<sup>28</sup>. Systematic review of case reports found higher COVID-19  
5 complication risk among COPD patients, but the effect of COPD severity was not  
6 investigated<sup>29</sup>. Patients with cystic fibrosis and sickle cell disease were regarded as high risk  
7 for COVID-19 complications based on expert opinions<sup>30,31</sup>. While pregnant women with  
8 COVID-19 were found to have higher risk of poor maternal and perinatal outcomes<sup>32,33</sup>,  
9 outcomes were not investigated specifically for pregnant women with heart disease. There  
10 was no evidence found for higher COVID-19 related complications for patients on various  
11 immunosuppressants<sup>34</sup>. A large community study in England found strong association  
12 between severe asthma (hazard ratio 1.25) and COVID-19 related mortality but they did not  
13 investigate the risk of COVID-19 infection or hospitalisation<sup>9</sup>.

14

15 In common with previous studies, we demonstrated that age was associated with one of the  
16 highest relative risks of death. Additionally, we showed the large extent to which age  
17 contributed to adverse outcomes at a population level with 79.14% of deaths attributable to  
18 age  $\geq 70$  years. The higher mortality in the elderly was mediated in part by their higher case-  
19 fatality but they also had a higher incidence of infection, possibly due to transmission within  
20 care homes. Their lower likelihood of being admitted to ICU once hospitalised for COVID-  
21 19 may have contributed to their higher case-fatality. Previous studies have reported that men  
22 are at highest risk of from COVID-19.<sup>7</sup> Our study demonstrated that men are less likely than  
23 women to be tested for COVID-19, less likely have confirmed infection and slightly less  
24 likely to be hospitalised. They have comparable overall mortality from COVID-19, due to  
25 their lower incidence, but their case-fatality is significantly higher.

1

2 Strengths and Limitations

3

4 This study adds to the existing evidence of the possible effectiveness of a shielding strategy  
5 which is currently limited to mathematical modelling of population effects based on  
6 assumptions<sup>11-19</sup>. Ours was a large-scale, unselected general population study. The data  
7 cover a period when shielding was in place. Linkage of primary care, laboratory, hospital and  
8 death data enabled us to examine a range of COVID-19 outcomes and study a range of  
9 exposure variables including the overall risk categories and their individual criteria. The  
10 datasets were linked using exact, rather than probabilistic, matching. We were able to adjust  
11 for potential sociodemographic confounders. The exposure data were collected prior to the  
12 outcomes occurring avoiding potential reverse causation and recall or recording bias. We did  
13 not have data on potential lifestyle confounding factors such as smoking and obesity, or  
14 ethnicity. We did not analyse multimorbidity or other potential risk factors not currently  
15 included in the high or moderate risk categories as the aim was to evaluate the current  
16 strategy. The shielding and moderate-risk criteria were correct at the time of extracting data  
17 but may be revised over time.

18

19 Implications of findings

20

21 Our findings suggest that our attempts to shield those at highest risk have not been as  
22 successful as hoped, with those advised to shield experiencing higher rates of infection and  
23 death. ICU provision has been successfully protected but via systematic exclusion of those  
24 with worse prognosis, rather than prevention of infection in those highest at risk. For  
25 shielding to be effective as a population level strategy, the current criteria would need to be



1 expanded since three-quarters of deaths were associated with moderate risk criteria for which  
2 shielding has not hitherto been recommended. In our study, more than one-quarter of the  
3 general population would have needed to be effectively shielded to prevent over 80% of  
4 deaths. Since this is unlikely to be acceptable at a time when governments are under pressure  
5 to ease lock-down restrictions, shielding is probably best viewed as an individual-level  
6 intervention to be used alongside other population-wide interventions such as physical  
7 distancing, face coverings and hand hygiene.

8

9

1 **Availability of data and materials**

2 The dataset supporting the conclusions of this article is available in the Glasgow Safe Haven  
3 (<https://www.nhsggc.org.uk/about-us/professional-support-sites/safe-haven/services/>).

4

5 **Acknowledgements**

6 We are extremely grateful to the following for their support and hard work in extracting and  
7 linking the datasets and providing access to them: Charlie Mayor (Data Safe Haven  
8 Manager), Alison Hamilton (Safe Haven Project Manager), Jonathan Todd (Head of  
9 Information Management), Imran Sadat (Data Manager) and Neil Hillen (Data Analyst).

10

11 **Funding**

12 No external funding sources.

13

14 **Conflicts of interest**

15 All authors have completed the ICMJE uniform disclosure form at  
16 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the  
17 submitted work; no financial relationships with any organisations that might have an interest  
18 in the submitted work in the previous three years; no other relationships or activities that  
19 could appear to have influenced the submitted work.

20

21 **Contributors**

22 FH and BJ contributed equally and are joint-first authors. BJ and JP conceptualised the study,  
23 interpreted the data, and wrote the first draft of the manuscript. FH analysed the data and  
24 wrote the first draft of the manuscript. All other authors interpreted the data and critically  
25 revised the manuscript. All authors approved the final submitted version of the manuscript.

1 BJ, FH, and JP serves as the guarantor of the manuscript and accepts full responsibility for  
2 the work and/or the conduct of the study, had access to the data, and controlled the decision  
3 to publish. The corresponding author attests that all listed authors meet authorship criteria  
4 and that no others meeting the criteria have been omitted.

## 5 **References**

- 6 1. Willan J, King AJ, Jeffery K, Bienz N. Challenges for NHS hospitals during covid-19  
7 epidemic. *BMJ*. 2020;368. doi:10.1136/BMJ.M1117
- 8 2. ACAPS. #COVID19 A global joint response.
- 9 3. Swedish Civil Contingencies Agency (MSB). National ban on visiting elderly homes.
- 10 4. Radtke T, Haile SR, Dressel H, Benden C. Recommended shielding against COVID-  
11 19 impacts physical activity levels in adults with cystic fibrosis. *J Cyst Fibros*.  
12 Published online 2020.
- 13 5. Kemp O, Horne GA, Soutar R. The psychological impact of COVID19 on a shielding  
14 high-risk cohort. *Scott Med J*. Published online 2020:0036933020951900.
- 15 6. Public Health England. Guidance on shielding and protecting people who are clinically  
16 extremely vulnerable from COVID-19.
- 17 7. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 —  
18 Studies Needed. *N Engl J Med*. 2020;382(13):1194-1196.  
19 doi:10.1056/NEJMp2002125
- 20 8. Lochlainn MN, Lee KA, Sudre CH, et al. Key predictors of attending hospital with  
21 COVID19: An association study from the COVID Symptom Tracker App in 2,618,948  
22 individuals. *medRxiv*. Published online April 2020:2020.04.25.20079251.  
23 doi:10.1101/2020.04.25.20079251
- 24 9. The OpenSAFELY, Williamson E, Walker AJ, et al. OpenSAFELY: factors associated  
25 with COVID-19-related hospital death in the linked electronic health records of 17  
26 million adult NHS patients. *medRxiv*. Published online May  
27 2020:2020.05.06.20092999. doi:10.1101/2020.05.06.20092999
- 28 10. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and  
29 prognosis of covid-19 infection: systematic review and critical appraisal. *BMJ*.  
30 2020;369:m1328. doi:10.1136/bmj.m1328
- 31 11. Vlas SJ de, Coffeng LE. A phased lift of control: a practical strategy to achieve herd  
32 immunity against Covid-19 at the country level. *medRxiv*. Published online 2020.  
33 doi:10.1101/2020.03.29.20046011
- 34 12. Keeling MJ, Hill E, Gorsich E, et al. Predictions of COVID-19 dynamics in the UK:  
35 short-term forecasting and analysis of potential exit strategies. *medRxiv*. Published  
36 online 2020. doi:10.1101/2020.05.10.20083683
- 37 13. McKeigue PM, Colhoun HM. Evaluation of “stratify and shield” as a policy option for  
38 ending the COVID-19 lockdown in the UK. *medRxiv*. Published online 2020.  
39 doi:10.1101/2020.04.25.20079913
- 40 14. Bunnik B Van, Woolhouse M, van Bunnik BAD. Segmentation and shielding of the  
41 most vulnerable members of the population as elements of an exit strategy from  
42 COVID-19 lockdown. *medrxiv*. Published online 2020.  
43 doi:10.1101/2020.05.04.20090597
- 44 15. Weitz JS, Beckett SJ, Coenen AR, et al. Intervention Serology and Interaction  
45 Substitution: Modeling the Role of “Shield Immunity” in Reducing COVID-19

- 1 Epidemic Spread. *medRxiv*. Published online 2020. doi:10.1101/2020.04.01.20049767
- 2 16. Neufeld Z, Khataee H. Targeted adaptive isolation strategy for Covid-19 pandemic.
- 3 *medRxiv*. Published online 2020. doi:10.1101/2020.03.23.20041897
- 4 17. Acemoglu D, Chernozhukov V, Werning I, Whinston M. *Optimal Targeted*
- 5 *Lockdowns in a Multi-Group SIR Model.*; 2020. doi:10.3386/w27102
- 6 18. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the
- 7 population at increased risk of severe COVID-19 due to underlying health conditions
- 8 in 2020: a modelling study. *Lancet Glob Heal*. Published online 2020.
- 9 doi:10.1016/S2214-109X(20)30264-3
- 10 19. Davies NG, Kucharski AJ, Eggo RM, et al. Effects of non-pharmaceutical
- 11 interventions on COVID-19 cases, deaths, and demand for hospital services in the UK:
- 12 a modelling study. *Lancet Public Heal*. Published online 2020. doi:10.1016/S2468-
- 13 2667(20)30133-X
- 14 20. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated
- 15 with the COVID-19 pandemic according to underlying conditions and age: a
- 16 population-based cohort study. *Lancet*. Published online 2020. doi:10.1016/s0140-
- 17 6736(20)30854-0
- 18 21. Clark A, Jit M, Warren-Gash C, et al. How many are at increased risk of severe
- 19 COVID-19 disease? Rapid global, regional and national estimates for 2020. *medRxiv*.
- 20 Published online 2020. doi:10.1101/2020.04.18.20064774
- 21 22. Adams ML, Katz DL, Grandpre J. Population based estimates of comorbidities
- 22 affecting risk for complications from COVID-19 in the US. *medRxiv*. Published online
- 23 2020. doi:10.1101/2020.03.30.20043919
- 24 23. Jin J, Agarwala N, Kundu P, Chatterjee N. Estimating the Size of High-risk
- 25 Populations for COVID-19 Mortality across 442 US Cities. Published online May
- 26 2020. doi:10.1101/2020.05.27.20115170
- 27 24. Pereira M, Mohan S, Cohen D, et al. COVID-19 in Solid Organ Transplant Recipients:
- 28 Initial Report From the US Epicenter. *Am J Transplant*. Published online 2020.
- 29 doi:10.1111/AJT.15941
- 30 25. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in Solid Organ Transplant
- 31 Recipients: A Single-Center Case Series From Spain. *Am J Transplant*. Published
- 32 online 2020. doi:10.1111/AJT.15929
- 33 26. Zhang L, Zhu F, Xie L, et al. Clinical Characteristics of COVID-19-infected Cancer
- 34 Patients: A Retrospective Case Study in Three Hospitals Within Wuhan, China. *Ann*
- 35 *Oncol Off J Eur Soc Med Oncol*. Published online 2020.
- 36 doi:10.1016/J.ANNONC.2020.03.296
- 37 27. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-
- 38 COV-2: a multi-center study during the COVID-19 outbreak. *Cancer Discov*.
- 39 Published online April 2020. doi:10.1158/2159-8290.CD-20-0422
- 40 28. He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers.
- 41 *Leukemia*. Published online April 2020:1-9. doi:10.1038/s41375-020-0836-7
- 42 29. Yang J, Zheng Y, Gou X, et al. Prevalence of Comorbidities and Its Effects in
- 43 Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis. *Int J*
- 44 *Infect Dis*. 2020;94. doi:10.1016/J.IJID.2020.03.017
- 45 30. Colombo C, Burgel P-R, Gartner S, et al. Impact of COVID-19 on people with cystic
- 46 fibrosis. *Lancet Respir Med*. 2020;8(5):e35-e36. doi:10.1016/S2213-2600(20)30177-6
- 47 31. Rodriguez-Morales A, Cardona-Ospina J, Gutiérrez-Ocampo E, et al. Clinical,
- 48 Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-
- 49 Analysis. *Travel Med Infect Dis*. Published online 2020.
- 50 doi:10.1016/J.TMAID.2020.101623

- 1 32. Di Mascio D, Khalil A, Saccone G, et al. Outcome of Coronavirus Spectrum Infections  
2 (SARS, MERS, COVID 1 -19) During Pregnancy: A Systematic Review and Meta-  
3 Analysis. *Am J Obstet Gynecol MFM*. Published online 2020.  
4 doi:10.1016/J.AJOGMF.2020.100107
- 5 33. Elshafeey F, Magdi R, Hindi N, et al. A Systematic Scoping Review of COVID-19  
6 During Pregnancy and Childbirth. *Int J Gynaecol Obstet*. Published online 2020.  
7 doi:10.1002/IJGO.13182
- 8 34. Minotti C, Tirelli F, Barbieri E, Giaquinto C, D D. How Is Immunosuppressive Status  
9 Affecting Children and Adults in SARS-CoV-2 Infection? A Systematic Review. *J*  
10 *Infect*. 2020;S0163-4453. doi:10.1016/J.JINF.2020.04.026  
11  
12

1 **Table 1.** COVID-19 testing status by sociodemographic characteristics, risk category and risk  
 2 criteria  
 3  
 4

	COVID-19 testing status		P value
	Not tested N=1,299,206 n (%)	Tested N=15,865 n (%)	
Age group (years)			<0.0001
0-24	355,238 (99.49)	1,822 (0.51)	
25-44	410,408 (99.22)	3,247 (0.78)	
45-64	340,268 (98.65)	4,660 (1.35)	
≥65	193,292 (96.92)	6,136 (3.08)	
Sex			<0.0001
Male	654,041 (99.01)	6,569 (0.99)	
Female	645,165 (98.58)	9,296 (1.42)	
Deprivation quintile			<0.0001
1 (most deprived)	461,672 (98.67)	6,211 (1.33)	
2	230,402 (98.75)	2,921 (1.25)	
3	194,702 (98.90)	2,175 (1.10)	
4	173,456 (98.93)	1,883 (1.07)	
5 (most affluent)	238,974 (98.89)	2,675 (1.11)	
Risk category			<0.0001
Low	928,397 (99.28)	6,767 (0.72)	
Moderate	340,473 (98.01)	6,901 (1.99)	
Shielded	30,336 (93.25)	2,197 (6.75)	
Moderate risk criteria			
Chronic respiratory disease	149,325 (98.33)	2,540 (1.67)	<0.0001
Heart disease	46,728 (96.21)	1,843 (3.79)	<0.0001
Hypertension	156,286 (97.55)	3,929 (2.45)	<0.0001
Diabetes	62,482 (97.09)	1,876 (2.91)	<0.0001
Weakened immune system	1,140 (95.40)	55 (4.60)	<0.0001
≥70 years of age	134,305 (96.23)	5,263 (3.77)	<0.0001
Shielded criteria			
Severe respiratory disease	17,146 (94.48)	1,001 (5.52)	<0.0001
Specific cancers	2,075 (83.30)	416 (16.70)	<0.0001
Pregnant with severe heart disease	<5	0	-
Immunosuppressive therapy	5,028 (94.00)	321 (6.00)	<0.0001
Solid organ transplant	1,149 (92.29)	96 (7.71)	<0.0001
Rare diseases and inborn errors of metabolism	1,623 (91.95)	142 (8.05)	<0.0001
Renal dialysis	6,216 (91.94)	545 (8.06)	<0.0001

5  
 6 N number

**Table 2.** Crude, population-level COVID-19 outcomes by sociodemographic characteristics, risk category and risk criteria

	Confirmed COVID-19 infection			COVID-19 hospitalisation			COVID-19 ICU admission			COVID-19 mortality		
	Negative test/ Not tested	Positive test	P-value	Not admitted	Admitted	P-value	Not admitted	Admitted	P-value	Alive	Dead	P-value
	N=1,311,723 n (%)	N=3,348 n (%)		N=1,313,410 n (%)	N=1,661 n (%)		N=1,314,949 n (%)	N=122 n (%)		N=1,314,044 n (%)	N=1,027 n (%)	
Age group (years)			<0.0001			<0.0001			0.0005			<0.0001
0-24	356,944 (99.97)	116 (0.03)		357,041 (99.99)	19 (0.01)		357,060 (100.00)	0		357,060 (100.00)	0 (0.00)	
25-44	413,123 (99.87)	532 (0.13)		413,532 (99.97)	123 (0.03)		413,643 (100.00)	12 (0.00)		413,647 (100.00)	8 (0.00)	
45-64	343,856 (99.69)	1,072 (0.31)		344,409 (99.85)	519 (0.15)		344,846 (99.98)	82 (0.02)		344,838 (99.97)	90 (0.03)	
≥65	197,800 (99.18)	1,628 (0.82)		198,428 (99.50)	1,000 (0.50)		199,400 (99.99)	28 (0.01)		198,499 (99.53)	929 (0.47)	
Sex			<0.0001			0.81			<0.0001			0.92
Male	659,203 (99.79)	1,407 (0.21)		659,781 (99.87)	829 (0.13)		660,525 (99.99)	85 (0.01)		660,092 (99.92)	518 (0.08)	
Female	652,250 (99.70)	1,941 (0.30)		659,369 (99.87)	832 (0.13)		660,908 (99.99)	37 (0.01)		653,952 (99.92)	509 (0.08)	
Deprivation quintile			0.0002			<0.0001			0.18			<0.0001
1 (most deprived)	466,582 (99.72)	1,301 (0.28)		467,146 (99.84)	737 (0.16)		467,832 (99.99)	51 (0.01)		467,442 (99.91)	441 (0.09)	
2	232,710 (99.74)	613 (0.26)		233,041 (99.88)	282 (0.12)		233,302 (99.99)	21 (0.01)		233,181 (99.94)	142 (0.06)	
3	196,416 (99.77)	461 (0.23)		196,651 (99.89)	226 (0.11)		196,854 (99.99)	23 (0.01)		196,724 (99.92)	153 (0.08)	
4	174,939 (99.77)	400 (0.23)		175,143 (99.89)	196 (0.11)		175,329 (99.99)	10 (0.01)		175,209 (99.93)	130 (0.07)	
5 (most affluent)	241,076 (99.76)	573 (0.24)		241,429 (99.91)	220 (0.09)		241,632 (99.99)	17 (0.01)		241,488 (99.93)	161 (0.07)	
Risk category			<0.0001			<0.0001			<0.0001			<0.0001
Low	933,977 (99.87)	1,187 (0.13)		934,768 (99.96)	396 (0.04)		935,099 (99.99)	65 (0.01)		935,081 (99.99)	83 (0.01)	
Moderate	345,552 (99.48)	1,822 (0.52)		346,372 (99.71)	1,002 (0.29)		347,325 (99.99)	49 (0.01)		346,572 (99.77)	802 (0.23)	
Shielded	32,194 (98.96)	339 (1.04)		32,270 (99.19)	263 (0.81)		32,525 (99.98)	8 (0.02)		32,391 (99.56)	142 (0.44)	
Moderate risk criteria												
Chronic respiratory disease	151,414 (99.70)	451 (0.30)	0.0005	151,618 (99.84)	247 (0.16)	<0.0001	151,853 (99.99)	12 (0.01)	0.65	151,812 (99.97)	53 (0.03)	<0.0001
Heart disease	48,176 (99.19)	395 (0.81)	<0.0001	48,325 (99.49)	246 (0.51)	<0.0001	48,564 (99.99)	7 (0.01)	0.34	48,456 (99.76)	115 (0.24)	<0.0001
Hypertension	159,267 (99.41)	948 (0.59)	<0.0001	159,670 (99.66)	545 (0.34)	<0.0001	160,189 (99.98)	26 (0.02)	0.003	159,991 (99.86)	224 (0.14)	<0.0001
Diabetes	63,903 (99.29)	455 (0.71)	<0.0001	64,063 (99.54)	295 (0.46)	<0.0001	64,335 (99.96)	23 (0.04)	<0.0001	64,263 (99.85)	95 (0.15)	<0.0001
Weakened immune system	1,183 (99.00)	12 (1.00)	<0.0001	1,185 (99.16)	10 (0.84)	<0.0001	1,195 (100.00)	0 (0.00)	-	1,189 (99.50)	6 (0.50)	<0.0001
≥70 years of age	138,115 (98.96)	1,453 (1.04)	<0.0001	138,701 (99.38)	867 (0.62)	<0.0001	139,560 (99.99)	8 (0.01)	0.19	138,690 (99.37)	878 (0.63)	<0.0001
Shielded group												
Severe respiratory disease	17,981 (99.09)	166 (0.91)	<0.0001	18,012 (99.26)	135 (0.74)	<0.0001	18,146 (99.99)	<5	-	18,059 (99.52)	88 (0.48)	<0.0001
Specific cancers	2,452 (98.43)	39 (1.57)	<0.0001	2,462 (98.84)	29 (1.16)	<0.0001	2,491 (100.00)	0	-	2,475 (99.36)	16 (0.64)	<0.0001
Pregnant, severe heart disease	<5	0	-	<5	0	-	<5	0	-	<5	0(0.00)	-
Immunosuppressive therapy	5,285 (98.80)	64 (1.20)	<0.0001	5,299 (99.07)	50 (0.93)	<0.0001	5,346 (99.94)	<5	-	5,324 (99.53)	25 (0.47)	<0.0001
Solid organ transplant	1,228 (98.63)	17 (1.37)	<0.0001	1,230 (98.80)	15 (1.20)	<0.0001	1,244 (99.92)	<5	-	1,238 (99.44)	7 (0.56)	<0.0001
Rare diseases and IEM	1,729 (97.96)	36 (2.04)	<0.0001	1,741 (98.64)	24 (1.36)	<0.0001	1,764 (99.94)	<5	-	1,744 (98.81)	21 (1.19)	<0.0001
Renal dialysis	6,684 (98.86)	77 (1.14)	<0.0001	6,704 (99.16)	57 (0.84)	<0.0001	6,758 (99.96)	<5	-	6,749 (99.82)	12 (0.18)	0.007

N number; IEM inborn errors of metabolism

**Table 3.** Associations\* between risk categories and risk criteria and population-level COVID-19 outcomes

	Confirmed COVID-19 infection		COVID-19 hospitalisation		COVID-19 ICU admission		COVID-19 mortality	
	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value
<b>Low</b>	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
<b>Moderate</b>								
Overall	4.11 (3.82-4.42)	<0.0001	6.82 (6.07-7.66)	<0.0001	2.06 (1.42-2.98)	0.0001	26.10 (20.89-32.60)	0.0001
Chronic respiratory disease	2.31 (2.07-2.57)	<0.0001	3.80 (3.24-4.45)	<0.0001	1.15 (0.62-2.14)	0.65	3.92 (2.80-5.50)	0.0001
Heart disease	6.54 (5.84-7.33)	<0.0001	11.75 (10.02-13.77)	<0.0001	1.92 (0.88-4.19)	0.1	26.30 (19.92-34.74)	0.0001
Hypertension	4.61 (4.23-5.02)	<0.0001	8.09 (7.11-9.20)	<0.0001	2.44 (1.55-3.84)	0.0001	15.87 (12.38-20.35)	0.0001
Diabetes	5.61 (5.03-6.24)	<0.0001	10.6 (9.12-12.32)	<0.0001	4.89 (3.04-7.88)	<0.0001	16.42 (12.29-21.93)	0.0001
Weakened immune system	7.81 (4.44-13.76)	<0.0001	19.82 (10.60-37.07)	<0.0001	-	-	56.85 (25.14-128.55)	0.0001
≥70 years of age	8.10 (7.50-8.74)	<0.0001	15.12 (13.42-17.03)	<0.0001	0.90 (0.43-1.86)	0.77	73.85 (59.45-91.75)	0.0001
<b>Shielded</b>								
Overall	7.91 (7.01-8.92)	<0.0001	18.47 (15.79-21.59)	<0.0001	3.67 (1.76-7.65)	0.0005	48.64 (37.23-63.56)	0.0001
Severe respiratory disease	6.82 (5.79-8.02)	<0.0001	16.59 (13.63-20.19)	<0.0001	-	-	53.52 (39.77-72.02)	0.0001
Specific cancers	12.16 (8.85-16.70)	<0.0001	27.49 (18.87-40.04)	<0.0001	-	-	72.55 (42.83-122.88)	0.0001
Immunosuppressive therapy	9.28 (7.23-11.92)	<0.0001	22.08 (16.47-29.61)	<0.0001	-	-	52.86 (34.03-82.11)	0.0001
Solid organ transplant	10.98 (6.82-17.67)	<0.0001	28.18 (16.85-47.12)	<0.0001	-	-	63.06 (29.50-134.80)	0.0001
Rare diseases and IEM	15.95 (11.47-22.18)	<0.0001	31.77 (21.06-47.91)	<0.0001	-	-	133.80 (83.50-214.41)	0.0001
Renal dialysis	8.76 (6.97-11.02)	<0.0001	19.66 (14.90-25.94)	<0.0001	-	-	20.03 (11.04-36.36)	0.0001

\*adjusted for sex and deprivation quintile

RR relative risk; CI confidence interval; IEM inborn errors of metabolism



**Table 4.** Crude COVID-19 outcomes among confirmed cases by sociodemographic characteristics, risk category and risk criteria

	COVID-19 hospitalisation N=3,348 <sup>†</sup>			COVID-19 ICU admission N=3,348 <sup>†</sup>			COVID-19 case-fatality N=3,846 <sup>‡</sup>		
	Not admitted N=1,687 n (%)	Admitted N=1,661 n (%)	P-value	Not admitted N=3,226 n (%)	Admitted N=122 n (%)	P-value	Alive N=2,819 n (%)	Dead N=1,027 n (%)	P-value
Age group (years)			<0.0001			<0.0001			<0.0001
0-24	97 (83.62)	19 (16.38)		116 (100.00)	0		116 (100.00)	0 (0.00)	
25-44	410 (76.92)	123 (23.08)		520 (97.74)	12 (2.26)		526 (98.50)	8 (1.50)	
45-64	553 (51.59)	519 (48.41)		990 (92.35)	82 (7.65)		1,003 (91.77)	90 (8.23)	
≥65	630 (38.65)	1,000 (61.35)		1,600 (98.28)	28 (1.72)		1,174 (55.83)	929 (44.17)	
Sex			<0.0001			<0.0001			<0.0001
Male	579 (41.12)	829 (58.88)		1,322 (93.96)	85 (6.04)		1,105 (68.08)	518 (31.92)	
Female	1,108 (57.11)	832 (42.89)		1,904 (98.09)	37 (1.91)		1,717 (77.10)	509 (22.90)	
Deprivation Quintile			<0.0001			0.29			0.0004
1 (most deprived)	566 (43.44)	737 (56.56)		1,250 (96.08)	51 (3.92)		1,046 (70.34)	441 (29.66)	
2	332 (54.07)	282 (45.93)		592 (96.57)	21 (3.43)		531 (78.90)	142 (21.10)	
3	235 (50.98)	226 (49.02)		438 (95.01)	23 (4.99)		394 (72.03)	153 (27.97)	
4	204 (51.00)	196 (49.00)		390 (97.50)	10 (2.50)		341 (72.40)	130 (27.60)	
5 (most affluent)	353 (61.61)	220 (38.39)		556 (97.03)	17 (2.97)		507 (75.90)	161 (24.10)	
Risk category			<0.0001			0.0001			<0.0001
Low	792 (66.67)	396 (33.33)		1,122 (94.52)	65 (5.48)		1,128 (93.15)	83 (6.85)	
Moderate	820 (45.01)	1,002 (54.99)		1,773 (97.31)	49 (2.69)		1,448 (64.36)	802 (35.64)	
Shielded	78 (22.87)	263 (77.13)		331 (97.64)	8 (2.36)		243 (63.12)	142 (36.88)	
Moderate risk criteria									
Chronic respiratory disease	205 (45.35)	247 (54.65)	0.02	439 (97.34)	12 (2.66)	0.29	420 (88.79)	53 (11.21)	<0.0001
Heart disease	149 (37.72)	246 (62.28)	<0.0001	388 (98.23)	7 (1.77)	0.049	330 (74.16)	115 (25.84)	0.7
Hypertension	404 (42.57)	545 (57.43)	<0.0001	922 (97.26)	26 (2.74)	0.10	836 (78.87)	224 (21.13)	<0.0001
Diabetes	161 (35.31)	295 (64.69)	<0.0001	432 (94.95)	23 (5.05)	0.11	398 (80.73)	95 (19.27)	<0.0001
Weakened immune system	2 (16.67)	10 (83.33)	0.04	12 (100.00)	0	-	6 (50.00)	6 (50.00)	0.13
≥70 years of age	587 (40.37)	867 (59.63)	<0.0001	1,445 (99.45)	8 (0.55)	<0.0001	1,035 (54.10)	878 (45.90)	<0.0001
Shielding criteria									
Severe respiratory disease	33 (19.64)	135 (80.36)	<0.0001	165 (99.40)	<5	-	111 (55.78)	88 (44.22)	<0.0001
Specific cancers	10 (25.64)	29 (74.36)	0.003	39 (100.00)	0	-	27 (62.79)	16 (37.21)	0.16
Pregnant, severe heart disease	-	-	-	-	-	-	-	-	-
Immunosuppressive therapy	14 (21.88)	50 (78.12)	<0.0001	61 (95.31)	<5	-	42 (62.69)	25 (37.31)	0.07
Solid organ transplant	2 (11.76)	15 (88.24)	0.003	16 (94.12)	<5	-	11 (61.11)	7 (38.89)	0.37
Rare diseases and IEM	12 (33.33)	24 (66.67)	0.06	35 (97.22)	<5	-	23 (52.27)	21 (47.73)	0.003
Renal dialysis	20 (25.97)	57 (74.03)	<0.0001	74 (96.10)	<5	-	66 (84.62)	12 (15.38)	0.03

<sup>†</sup>laboratory-confirmed (test-positive) COVID-19 cases

<sup>‡</sup>clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases

N number; IEM inborn errors of metabolism

**Table 5.** Associations\* between risk categories and risk criteria and COVID-19 outcomes among confirmed cases

	COVID-19 hospitalisation N=3,348 <sup>†</sup>		COVID-19 ICU admission N=3,348 <sup>†</sup>		COVID-19 case-fatality N=3,846 <sup>‡</sup>	
	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value
<b>Low</b>	1 (Reference)		1 (Reference)		1 (Reference)	
<b>Moderate</b>						
Overall	1.33 (1.22-1.46)	<0.0001	0.38 (0.26-0.55)	< 0.0001	5.13 (4.24-6.21)	<0.0001
Chronic respiratory disease	1.56 (1.39-1.76)	<0.0001	0.46 (0.25-0.86)	0.02	1.63 (1.22-2.18)	0.001
Heart disease	1.60 (1.42-1.81)	<0.0001	0.24 (0.11-0.53)	0.0004	3.57 (2.81-4.54)	<0.0001
Hypertension	1.54 (1.40-1.70)	<0.0001	0.44 (0.28-0.69)	0.0004	3.06 (2.48-3.79)	<0.0001
Diabetes	1.71 (1.52-1.91)	<0.0001	0.72 (0.45-1.18)	0.19	2.65 (2.06-3.40)	<0.0001
Weakened immune system	2.43 (1.51-3.89)	0.0002	-	-	7.14 (3.54-14.39)	<0.0001
≥70 years of age	1.37 (1.25-1.49)	<0.0001	0.07 (0.04-0.15)	< 0.0001	6.59 (5.46-7.96)	<0.0001
<b>Shielded</b>						
Overall	1.96 (1.74-2.21)	<0.0001	0.33 (0.16-0.70)	0.004	5.19 (4.12-6.53)	<0.0001
Severe respiratory disease	1.94 (1.67-2.25)	<0.0001	-	-	6.23 (4.83-8.03)	<0.0001
Specific cancers	1.89 (1.42-2.51)	<0.0001	-	-	5.04 (3.21-7.93)	<0.0001
Immunosuppressive therapy	2.17 (1.74-2.71)	<0.0001	-	-	5.19 (3.56-7.58)	<0.0001
Solid organ transplant	2.33 (1.58-3.44)	<0.0001	-	-	5.24 (2.73-10.07)	<0.0001
Rare diseases and IEM	1.50 (1.10-2.05)	0.01	-	-	6.64 (4.42-9.96)	<0.0001
Renal dialysis	2.15 (1.74-2.65)	<0.0001	-	-	2.20 (1.32-3.66)	0.003

\*adjusted for sex and deprivation quintile

<sup>†</sup>laboratory-confirmed (test-positive) COVID-19 cases

<sup>‡</sup>clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases

N number; RR relative risk; CI confidence interval; IEM inborn errors of metabolism